Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters











Publication year range
2.
J Pediatr Genet ; 12(4): 348-351, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38162163

ABSTRACT

Leukocyte adhesion deficiency-III (LAD-III) is a rare genetic disease caused by defective integrin activation in hematopoietic cells due to mutations in the FERMT3 gene. The PTPRQ gene encodes the protein tyrosine phosphatase receptor Q and is essential for the normal maturation and function of hair bundle in the cochlea. Homozygous PTPRQ mutations impair the stereocilia in hair cells which lead to nonsyndromic sensorineural hearing loss (SNHL) with vestibular dysfunction. Here, we report two novel pathogenic homozygous mutations found in two genes, FERMT3 and PTPRQ , in a Brazilian patient with LAD-III and SNHL, which may develop our understanding of the phenotype-genotype correlation and prognosis of patients with these rare diseases.

4.
Fink, Thais T.; Marques, Heloisa H.S.; Gualano, Bruno; Lindoso, Livia; Bain, Vera; Astley, Camilla; Martins, Fernanda; Matheus, Denise; Matsuo, Olivia M.; Suguita, Priscila; Trindade, Vitor; Paula, Camila S.Y.; Farhat, Sylvia C.L.; Palmeira, Patricia; Leal, Gabriela N.; Suzuki, Lisa; Odone Filho, Vicente; Carneiro-Sampaio, Magda; Duarte, Alberto José S.; Antonangelo, Leila; Batisttella, Linamara R.; Polanczyk, Guilherme V.; Pereira, Rosa Maria R.; Carvalho, Carlos Roberto R.; Buchpiguel, Carlos A.; Xavier, Ana Claudia L.; Seelaender, Marilia; Silva, Clovis Artur; Pereira, Maria Fernanda B.; Sallum, Adriana M. E.; Brentani, Alexandra V. M.; Neto, Álvaro José S.; Ihara, Amanda; Santos, Andrea R.; Canton, Ana Pinheiro M.; Watanabe, Andreia; Santos, Angélica C. dos; Pastorino, Antonio C.; Franco, Bernadette D. G. M.; Caruzo, Bruna; Ceneviva, Carina; Martins, Carolina C. M. F.; Prado, Danilo; Abellan, Deipara M.; Benatti, Fabiana B.; Smaria, Fabiana; Gonçalves, Fernanda T.; Penteado, Fernando D.; Castro, Gabriela S. F. de; Gonçalves, Guilherme S.; Roschel, Hamilton; Disi, Ilana R.; Marques, Isabela G.; Castro, Inar A.; Buscatti, Izabel M.; Faiad, Jaline Z.; Fiamoncini, Jarlei; Rodrigues, Joaquim C.; Carneiro, Jorge D. A.; Paz, Jose A.; Ferreira, Juliana C.; Ferreira, Juliana C. O.; Silva, Katia R.; Bastos, Karina L. M.; Kozu, Katia; Cristofani, Lilian M.; Souza, Lucas V. B.; Campos, Lucia M. A.; Silva Filho, Luiz Vicente R. F.; Sapienza, Marcelo T.; Lima, Marcos S.; Garanito, Marlene P.; Santos, Márcia F. A.; Dorna, Mayra B.; Aikawa, Nadia E.; Litvinov, Nadia; Sakita, Neusa K.; Gaiolla, Paula V. V.; Pasqualucci, Paula; Toma, Ricardo K.; Correa-Silva, Simone; Sieczkowska, Sofia M.; Imamura, Marta; Forsait, Silvana; Santos, Vera A.; Zheng, Yingying; HC-FMUSP Pediatric Post-COVID-19 Study Group.
Clinics ; Clinics;76: e3511, 2021. tab
Article in English | LILACS | ID: biblio-1350613

ABSTRACT

OBJECTIVES: To prospectively evaluate demographic, anthropometric and health-related quality of life (HRQoL) in pediatric patients with laboratory-confirmed coronavirus disease 2019 (COVID-19) METHODS: This was a longitudinal observational study of surviving pediatric post-COVID-19 patients (n=53) and pediatric subjects without laboratory-confirmed COVID-19 included as controls (n=52) was performed. RESULTS: The median duration between COVID-19 diagnosis (n=53) and follow-up was 4.4 months (0.8-10.7). Twenty-three of 53 (43%) patients reported at least one persistent symptom at the longitudinal follow-up visit and 12/53 (23%) had long COVID-19, with at least one symptom lasting for >12 weeks. The most frequently reported symptoms at the longitudinal follow-up visit were headache (19%), severe recurrent headache (9%), tiredness (9%), dyspnea (8%), and concentration difficulty (4%). At the longitudinal follow-up visit, the frequencies of anemia (11% versus 0%, p=0.030), lymphopenia (42% versus 18%, p=0.020), C-reactive protein level of >30 mg/L (35% versus 0%, p=0.0001), and D-dimer level of >1000 ng/mL (43% versus 6%, p=0.0004) significantly reduced compared with baseline values. Chest X-ray abnormalities (11% versus 2%, p=0.178) and cardiac alterations on echocardiogram (33% versus 22%, p=0.462) were similar at both visits. Comparison of characteristic data between patients with COVID-19 at the longitudinal follow-up visit and controls showed similar age (p=0.962), proportion of male sex (p=0.907), ethnicity (p=0.566), family minimum monthly wage (p=0.664), body mass index (p=0.601), and pediatric pre-existing chronic conditions (p=1.000). The Pediatric Quality of Live Inventory 4.0 scores, median physical score (69 [0-100] versus 81 [34-100], p=0.012), and school score (60 [15-100] versus 70 [15-95], p=0.028) were significantly lower in pediatric patients with COVID-19 at the longitudinal follow-up visit than in controls. CONCLUSIONS: Pediatric patients with COVID-19 showed a longitudinal impact on HRQoL parameters, particularly in physical/school domains, reinforcing the need for a prospective multidisciplinary approach for these patients. These data highlight the importance of closer monitoring of children and adolescents by the clinical team after COVID-19.


Subject(s)
Humans , Male , Child , Adolescent , COVID-19/complications , Quality of Life , Prospective Studies , Tertiary Care Centers , COVID-19 Testing , SARS-CoV-2 , Latin America
5.
Ann Hematol ; 97(11): 2039-2046, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29978284

ABSTRACT

In a prospective randomized study, treatment for aplastic anemia (AA) with rabbit antithymocyte globulin (r-ATG) and cyclosporine showed inferior hematological response and survival in comparison to horse antithymocyte globulin (h-ATG) and cyclosporine. However, h-ATG was discontinued in most Asian, South American, and European countries, where r-ATG became the only ATG formulation available. We retrospectively evaluated consecutive patients with acquired AA who received either rabbit (n = 170) or horse (n = 85) ATG and cyclosporine for first-line treatment from 1992 to 2014 in seven referral centers in Brazil and Argentina. Overall response at 3 months was 17% (95%CI, 11-23%) for r-ATG and 44% (95%CI, 33-55%) for h-ATG (p < 0.001). At 6 months, it was 31% (95%CI, 34-39%) for r-ATG and 59% (95%CI, 48-69%) for h-ATG (p < 0.001). Overall survival at 5 years was 57% (95%CI, 47-65%) for r-ATG and 80% (95%CI, 69-87%) for h-ATG (log-rank = 0.001). Relapse was significantly higher in patients receiving h-ATG (28%; 95%CI, 17-43%) as compared to r-ATG (9.4%; 95%CI, 4-21%; log-rank, p = 0.01). The type of ATG was the only factor associated with both response and survival. The r-ATG dose varied from 1 to 5 mg/kg/day, but it did not correlate with outcomes. In summary, this is the largest multicenter study comparing the two ATG formulations in AA. Our results indicate that the dose of r-ATG does not influence hematologic response or survival in first-line therapy for acquired AA. Considering the toxicity and costs of r-ATG, our findings challenge its aggregate benefit to cyclosporine therapy and further strengthen that h-ATG should remain standard therapy in AA.


Subject(s)
Anemia, Aplastic/drug therapy , Anemia, Aplastic/mortality , Antilymphocyte Serum/administration & dosage , Cyclosporine/administration & dosage , Adolescent , Adult , Aged , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Infant , Male , Middle Aged , Retrospective Studies , Survival Rate
6.
Ann Hematol ; 96(11): 1907-1914, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28815305

ABSTRACT

Despite being recommended as first-line immunosuppressive therapy in severe aplastic anemia (SAA), horse antithymocyte globulin (ATG) is still unavailable in many countries outside the USA. Rabbit ATG is more lymphocytoxic than horse ATG, and this might result in a higher incidence of severe infections and early mortality. This study was designed to identify the risk factors for early mortality and overall survival (OS) after rabbit ATG in patients with SAA. We retrospectively reviewed 185 patients with SAA who underwent rabbit ATG and cyclosporine. The incidence of death in 3 months following rabbit ATG therapy was 15.1% (28/185). Early mortality was mainly related to infectious complications, despite adequate antibiotic and/or antifungal treatment. Age > 35 years (odds ratio [OR] 5.06, P = 0.001) and baseline absolute neutrophil count (ANC) ≤ 0.1 × 109/L (OR 7.64, P < 0.001) were independent risk factors for early mortality after immunosuppressive therapy with this agent. Hematological response at 6 months was observed in only 29.7% of all patients. OS at 1 year after rabbit ATG was 75.3%; and age > 35 years (OR 1.88, P = 0.03), baseline ANC ≤ 0.1 × 109/L (OR 2.65, P < 0.001), and lack of response to rabbit ATG (OR 11.40, P < 0.001) were independently associated with mortality. Alternative strategies are needed for the treatment of SAA patients in countries were horse ATG is unavailable, particularly for those at high risk for early mortality after rabbit ATG due to a higher age and very low pre-treatment neutrophil count.


Subject(s)
Anemia, Aplastic/drug therapy , Anemia, Aplastic/mortality , Antilymphocyte Serum/administration & dosage , Immunosuppressive Agents/administration & dosage , Severity of Illness Index , Adolescent , Adult , Aged , Anemia, Aplastic/diagnosis , Animals , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Middle Aged , Mortality/trends , Predictive Value of Tests , Rabbits , Retrospective Studies , Treatment Outcome , Young Adult
7.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;32(supl.2): 45-48, jun. 2010.
Article in Portuguese | LILACS | ID: lil-560734

ABSTRACT

A deficiência de ferro é o distúrbio nutricional mais comum no mundo e constitui a maior causa de anemia associada às condições onde há erro alimentar, perda crônica de sangue ou quando ocorre o crescimento rápido, como na infância, na gravidez e na adolescência. Esta deficiência acarreta prejuízos no desenvolvimento neuropsicomotor, na capacidade de aprendizagem, no apetite, no crescimento e na resposta do sistema imunológico. Na adolescência, além de com frequência observarmos hábitos alimentares inadequados, estão presentes intensas mudanças fisiológicas e psicossociais que, em associação, podem comprometer o crescimento e aumentar o risco do desenvolvimento de deficiência de ferro e outras carências nutricionais, sobretudo na fase púbere. Desta forma, o diagnóstico de deficiência de ferro entre os adolescentes deve ser lembrado a fim de que medidas possam ser tomadas para diminuir a incidência de anemia, do comprometimento do rendimento escolar e do sistema imunológico, neste período da vida.


Iron deficiency is the most common nutritional disorder in the world and is a major cause of anemia associated with situations involving chronic blood loss or rapid growth such as during infancy, pregnancy and adolescence. This deficiency leads to impairment in psychomotor development, learning ability, appetite, growth and immune response. In adolescence, inadequate dietary habits are often observed and intensive physiological and psychological changes are seen that when combined can impair growth and increase the risk of developing iron deficiency or other nutritional disorders, especially during puberty. Thus, the diagnosis of iron deficiency among adolescents should always be considered so that measures can be taken to reduce the incidence of anemia, impairment of the immune system and improve school performance.


Subject(s)
Humans , Male , Female , Adolescent , Adolescent , Iron Deficiencies/diagnosis , Iron Deficiencies/metabolism , Iron Deficiencies/prevention & control
8.
Rev. bras. hematol. hemoter ; Rev. bras. hematol. hemoter;31(5): 397-399, 2009. graf
Article in Portuguese | LILACS | ID: lil-533599

ABSTRACT

A aplasia de medula é uma das mais raras (<1 por cento) e sérias complicações após o transplante hepático por insuficiência hepática aguda grave viral não A, não B e não C. Esta condição clínica, que acomete simultaneamente o tecido hepático e o hematopoético, foi descrita pela primeira vez em 1987, por Stock, e a fisiopatologia relacionada é uma condição imunomediada, provavelmente secundária à infecção viral desconhecida, e associada a grave prognóstico. A recuperação espontânea da aplasia medular adquirida habitualmente é muito rara e 50 por cento-70 por cento dos pacientes respondem ao tratamento imunossupressor com ciclosporina A (CsA) e glubulina antitimocítica (ATG), mesmo após o transplante hepático. Além do tratamento imunossupressor, outra opção é o transplante de medula óssea (TMO). Apresentamos o caso de uma criança com aplasia medular grave após transplante hepático, por insuficiência hepática aguda grave, que recebeu tratamento imunossupressor com CsA e ATG e evoluiu com recuperação completa das três séries do hemograma.


Aplastic anemia (AA) is one of the rarest (<1 percent) and most serious complications of liver transplantation for fulminant non-A, non-B and non-C hepatitis. It was first described in 1987 by Stock; the mechanism involved is an immunologically mediated condition secondary to an unknown viral infection. The disease is associated with a dismal prognosis. Spontaneous recovery from acquired AA is very rare however some patients (50-70 percent) recover after immunosuppressive therapy, such as Cyclosporin A (CsA) and Antithymocyte globulin (ATG), even after liver transplantation. Another treatment option is bone marrow transplantation. We report on a child who developed AA following liver transplantation for fulminant viral hepatitis that was treated with intensive immunosuppression including CsA and ATG and achieved complete recovery.


Subject(s)
Humans , Male , Child , Anemia, Aplastic , Bone Marrow Diseases , Bone Marrow Transplantation , Liver Transplantation/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL